BC
Birchview Capital Portfolio holdings
AUM
$101M
This Quarter Return
+7.33%
1 Year Return
+34.62%
3 Year Return
+103.2%
5 Year Return
+107.72%
10 Year Return
+352.1%
AUM
$123M
AUM Growth
+$123M
(+6.4%)
Cap. Flow
+$4.41M
Cap. Flow
% of AUM
3.59%
Top 10 Holdings %
Top 10 Hldgs %
65.43%
Holding
71
New
10
Increased
12
Reduced
8
Closed
3
Top Buys
| 1 |
Prothena Corp
PRTA
|
$1.32M |
| 2 |
DocGo
DCGO
|
$1.06M |
| 3 |
Treace Medical Concepts
TMCI
|
$692K |
| 4 |
Ultragenyx Pharmaceutical
RARE
|
$673K |
| 5 |
Castle Biosciences
CSTL
|
$533K |
Top Sells
| 1 |
Alphatec Holdings
ATEC
|
$1.29M |
| 2 |
Acadia Pharmaceuticals
ACAD
|
$1.14M |
| 3 |
Coherus Oncology, Inc. Common Stock
CHRS
|
$400K |
| 4 |
Progyny
PGNY
|
$369K |
| 5 |
Elutia
ELUT
|
$358K |
Sector Composition
| 1 | Healthcare | 96.88% |
| 2 | Energy | 3.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Bristol-Myers Squibb
BMY
$96B
| $38.8M | 31.53% |
685,182
-1,000
| -0.1% | -$56.6K |
|
2
Biodesix
BDSX
$62.6M
| $8.78M | 7.14% |
5,736,113
+40,000
| +0.7% | +$61.2K |
|
|
3
Acadia Pharmaceuticals
ACAD
$4.38B
| $6.21M | 5.05% |
338,400
-62,000
| -15% | -$1.14M |
|
|
4
Elutia
ELUT
$96.7M
| $4.58M | 3.73% |
1,225,489
-95,726
| -7% | -$358K |
|
|
5
Prothena Corp
PRTA
$441M
| $4.22M | 3.43% |
304,574
+95,000
| +45% | +$1.32M |
|
6
Neurocrine Biosciences
NBIX
$13.8B
| $4.13M | 3.36% |
30,240
| – | – |
|
7
Corcept Therapeutics
CORT
$7.35B
| $3.73M | 3.03% |
74,000
| – | – |
|
8
United Therapeutics
UTHR
$13.8B
| $3.53M | 2.87% |
10,000
| – | – |
|
9
Axogen
AXGN
$743M
| $3.25M | 2.64% |
197,000
| – | – |
|
|
10
DocGo
DCGO
$153M
| $3.24M | 2.64% |
764,062
+249,062
| +48% | +$1.06M |
|
11
QuidelOrtho
QDEL
$1.95B
| $3.01M | 2.45% |
67,619
| – | – |
|
12
Phreesia
PHR
$1.88B
| $2.89M | 2.35% |
114,700
| – | – |
|
13
Travere Therapeutics
TVTX
$1.56B
| $2.58M | 2.1% |
148,000
| – | – |
|
14
Masimo
MASI
$7.59B
| $2.53M | 2.06% |
15,280
| – | – |
|
15
Harrow
HROW
$1.44B
| $2.45M | 1.99% |
72,910
| – | – |
|
16
Stoke Therapeutics
STOK
$1.08B
| $2.32M | 1.88% |
210,000
| – | – |
|
17
Ovintiv
OVV
$10.8B
| $2.11M | 1.72% |
52,200
| – | – |
|
|
18
Castle Biosciences
CSTL
$696M
| $2.08M | 1.69% |
78,000
+20,000
| +34% | +$533K |
|
19
Protagonist Therapeutics
PTGX
$3.67B
| $1.85M | 1.51% |
48,000
| – | – |
|
20
EQT Corp
EQT
$32.4B
| $1.6M | 1.3% |
34,619
| – | – |
|
21
Foghorn Therapeutics
FHTX
$286M
| $1.47M | 1.19% |
310,930
-10,000
| -3% | -$47.2K |
|
22
Alkermes
ALKS
$4.78B
| $1.44M | 1.17% |
50,000
| – | – |
|
|
23
Treace Medical Concepts
TMCI
$464M
| $1.2M | 0.98% |
161,350
+93,000
| +136% | +$692K |
|
24
NovoCure
NVCR
$1.38B
| $924K | 0.75% |
31,000
+11,000
| +55% | +$328K |
|
25
10x Genomics
TXG
$1.74B
| $718K | 0.58% |
50,000
+20,000
| +67% | +$287K |
|